MAYO CLINIC

AI is transforming healthcare, with the World Economic Forum highlighting its potential for early disease detection and clinical assistance. Avant Technologies, Inc. (OTCQB: AVAI) is advancing AI in healthcare through a joint venture with Ainnova Tech Inc., focusing on a low-cost retinal camera integrated with Vision AI software. The AI in Healthcare Market is projected to grow to $148.4 billion by 2029, driven by strategic investments and innovation.

Dr. Greg J. Griepentrog joins Mayo Clinic in Rochester, MN, bringing expertise in pediatric oculoplastic research and upper facial, lacrimal, and orbital surgery. His dedication to patient care and research aligns with Mayo Clinic's values.

Mayo Clinic offers voretigene neparvovec-rzyl, the first FDA-approved retinal gene therapy for Leber congenital amaurosis due to biallelic RPE65 mutations, potentially restoring visual cycle and improving functional vision. Ongoing clinical trials explore treatments for Stargardt disease, retinal dystrophies, retinitis pigmentosa, and X-linked retinitis pigmentosa.

Attruby, the first FDA-approved near-complete TTR stabilizer, reduces cardiovascular death and hospitalizations in ATTR-CM patients, with rapid benefits seen in as few as 3 months. BridgeBio will provide Attruby free for life to U.S. clinical trial participants and offers extensive access programs.

Attruby, a near-complete TTR stabilizer, is the first FDA-approved treatment for ATTR-CM, reducing cardiovascular death and hospitalizations. It demonstrated rapid benefits, with a 42% reduction in composite ACM and recurrent CVH events, and a 50% reduction in CVH events at Month 30. BridgeBio will provide Attruby free for life to U.S. clinical trial participants and offers extensive access programs. The company will receive a $500 million payment under its royalty funding agreement and plans global approvals, starting with Europe in 2025.

Miguel Rosa-Grilo presented a new MRI technology at the Clinical Trials on Alzheimer’s Disease conference that reduces scan time by two-thirds without compromising image quality. This advancement could alleviate bottlenecks in Alzheimer’s diagnosis and care, making scans more patient-friendly. Clifford Jack supports this direction, noting the need for faster MRIs to handle increased patient loads. The new method, using Wave-Controlled Aliasing in Parallel Imaging, was tested on 90 patients with nearly identical results to standard scans, suggesting its potential for both diagnosis and monitoring treatment side effects like ARIA.

The FDA approved acoramidis (Attruby) for transthyretin amyloid cardiomyopathy (ATTR-CM), reducing cardiovascular death and hospitalization. Acoramidis, an orally-administered TTR stabilizer, showed a 42% reduction in mortality and recurrent hospitalization events at Month 30 in a phase 3 trial.

BridgeBio Pharma's Attruby™ (acoramidis) approved by FDA for ATTR-CM, reducing cardiovascular death and hospitalization by 42% at 30 months, with rapid benefits within 3 months and 50% reduction in cardiovascular-related hospitalizations. Attruby is the first near-complete TTR stabilizer (≥90%) preserving native TTR function.

FDA approves Attruby (acoramidis) to reduce cardiovascular death and hospitalization in patients with ATTR-CM, based on positive ATTRibute-CM Phase 3 study results.

GE HealthCare, since spinning off from GE in 2023, has grown revenue and invested $2.2 billion into innovation, focusing on AI, digital solutions, and expanding global reach. At its first Investor Day, leaders outlined plans for mid-single-digit organic revenue growth by 2026-2028, emphasizing innovation, new product development, and emerging markets. The company's D3 digital strategy aims to deliver precision care, leveraging AI to address healthcare challenges and improve patient outcomes.